Dynamic Technology Lab Private Ltd increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 242.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,993 shares of the company’s stock after acquiring an additional 5,659 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in IDEXX Laboratories were worth $1,243,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. D.A. Davidson & CO. boosted its stake in IDEXX Laboratories by 160.4% during the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock worth $100,000 after acquiring an additional 385 shares in the last quarter. Sun Life Financial INC raised its holdings in IDEXX Laboratories by 9,085.7% during the second quarter. Sun Life Financial INC now owns 643 shares of the company’s stock worth $104,000 after buying an additional 636 shares during the last quarter. BB&T Investment Services Inc. acquired a new position in IDEXX Laboratories during the second quarter worth $104,000. Capital Advisors Ltd. LLC acquired a new position in IDEXX Laboratories during the second quarter worth $128,000. Finally, Coastline Trust Co acquired a new position in IDEXX Laboratories during the second quarter worth $202,000. 88.41% of the stock is currently owned by institutional investors and hedge funds.

Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) traded up $0.80 during mid-day trading on Monday, hitting $154.88. 512,700 shares of the stock traded hands, compared to its average volume of 712,807. The stock has a market capitalization of $13,508.43, a P/E ratio of 52.15, a P/E/G ratio of 2.34 and a beta of 0.46. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. IDEXX Laboratories, Inc. has a 52 week low of $113.47 and a 52 week high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.05. The company had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.62 earnings per share. equities research analysts predict that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.

WARNING: “IDEXX Laboratories, Inc. (IDXX) Shares Bought by Dynamic Technology Lab Private Ltd” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/20/idexx-laboratories-inc-idxx-shares-bought-by-dynamic-technology-lab-private-ltd.html.

In other news, Director Rebecca M. Henderson sold 5,156 shares of the stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $153.29, for a total value of $790,363.24. Following the completion of the sale, the director now owns 17,274 shares in the company, valued at $2,647,931.46. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Rebecca M. Henderson sold 2,578 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $152.86, for a total transaction of $394,073.08. Following the completion of the sale, the director now owns 17,274 shares of the company’s stock, valued at approximately $2,640,503.64. The disclosure for this sale can be found here. In the last quarter, insiders sold 128,734 shares of company stock valued at $19,518,766. 2.77% of the stock is currently owned by corporate insiders.

IDXX has been the topic of several research reports. Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. Stifel Nicolaus restated a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a report on Monday, August 21st. Canaccord Genuity restated a “buy” rating and set a $180.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, August 22nd. BidaskClub downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, CL King upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price objective on the stock in a report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $173.67.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Stock Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related stocks with our FREE daily email newsletter.